BioSpace News Archive

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 3, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2022.

Biomea Fusion, Inc. (“Biomea”)(Nasdaq: BMEA) today announced the dosing of the first patient in the CLL cohort of COVALENT-101, the company’s ongoing Phase I clinical trial evaluating BMF-219, Biomea’s investigational covalent menin inhibitor, in patients with R/R AML, ALL, DLBCL, MM, and now CLL.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the third quarter ended September 30, 2022, after the close of the market on Thursday, November 3, 2022.

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, provided highlights from its Head and Neck Cancer Key Opinion Leader Roundtable.

Precision Optics Corporation, Inc. (OTCQB: PEYE) (the “Company”) announced today that the Company is amending the date for its reverse stock split, due to an unanticipated delay in obtaining necessary regulatory clearances.

Ardelyx, Inc. today announced that it will hold a conference call on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time to review third quarter 2022 financial results and provide a business overview.

Aspen Surgical Products, Inc. (“Aspen”), a portfolio company of Audax Private Equity (“Audax”) and a leader in disposable surgical products, announced the acquisition of Symmetry Surgical (“Symmetry”) from RoundTable Healthcare Partners. Symmetry represents Aspen’s 15th acquisition in total and sixth since Audax’ initial investment in Aspen in 2019.

Agiliti Inc. (NYSE: AGTI) (“Agiliti”) today announced that the company will release its third quarter results after the market close on Thursday, November 10, 2022, to be followed by a conference call at 5 p.m. Eastern Time on the same day.

Ignyte Acquisition Corp. today announced that Ignyte’s stockholders have approved its proposed business combination (the “Business Combination”) with Peak Bio Co., Ltd. (“Peak Bio”) at a Special Meeting of its stockholders held on October 25, 2022 (the “Special Meeting”).

Neurocrine Biosciences, Inc. today announced the first patient has been randomized for its Phase 2 placebo-controlled, inpatient clinical study evaluating the efficacy, safety, tolerability, and pharmacokinetics of investigational compound NBI-1117568 in adults with schizophrenia.